Lataa...
Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors
With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...
Tallennettuna:
| Julkaisussa: | Oncologist |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Inc.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/ https://ncbi.nlm.nih.gov/pubmed/30679319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|